A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

被引：1

作者：

Ross, David M. ^{[1
]}

Arbelaez, Alejandro ^{[2
]}

Chee, Lynette C. Y. ^{[3
]}

Fong, Chun Yew ^{[4
]}

Hiwase, Devendra ^{[5
]}

Kannourakis, George ^{[6
]}

Kwan, John ^{[7
]}

Liang, James ^{[8
]}

Puliyayi, Anish ^{[9
]}

Rose, Hannah ^{[10
]}

Tan, Shuhying ^{[11
]}

Teh, Tse-Chieh ^{[12
]}

esterman, David Alan ^{[13
]}

Wight, Joel

Rovaldi, Chris

Furutani, Elissa M.

Gaggi, Adrienne

Jiang, Ying

Lachey, Jenn

Natarajan, Harveen Dhillon

Ordonez, Claudia

机构：

[1] Flinders Med Ctr & Univ, Dept Haematol, Adelaide, SA, Australia

[2] Tweed Hosp, Brisbane, Qld, Australia

[3] Peter MacCallum Canc Ctr & Royal Melbourne Hosp, Dept Clin Haematol & Bone Marrow Transplant Serv, Melbourne, Vic, Australia

[4] Austin Hlth & Olivia Newton John Canc Res Inst, Dept Clin Haematol, Melbourne, Australia

[5] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia

[6] Ballarat Onc & Hem Serv, Ballarat, Vic, Australia

[7] Westmead Hosp, Sydney, NSW, Australia

[8] Middlemore Hosp, Auckland, New Zealand

[9] Barwon Hlth, Geelong, Vic, Australia

[10] Box Hill Hosp, Victoria, Australia

[11] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia

[12] Townsville Univ Hosp, NS Biopharma Marblehead MA, Townsville, Qld, Australia

[13] Keros Therapeut, Lexington, MA USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-147335

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3675

引用

页码：3675 / +

页数：5

共 50 条

[1] Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Faderl, Stefan
Estrov, Zeev
Yang, Hui
Maddipoti, Sirisha
Godley, Lucy A.
Gabrail, Nashat
Berdeja, Jesus G.
Nadeem, Ahmed
Kassalow, Laurent
Kantarjian, Hagop
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2548 - +
[2] Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes
Chee, Lynette C. Y.
Ross, David M.
Tan, Shuh Ying
Wight, Joel
Kannourakis, George
Ross, Miranda
Feng, Wei
Jiang, Ying
Natarajan, Harveen Dhillon
Graham, Christine
Rovaldi, Christopher
Cooper, Simon
Salstrom, Jen L.
BLOOD, 2022, 140 : 8181 - 8183
[3] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Faderl, Stefan
Estrov, Zeev
Godley, Lucy
Gabrail, Nashat Y.
Berdeja, Jesus G.
Nadeem, Ahmed
Stein, Karen
Noble, Yvonne
Kassalow, Laurent
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1628 - 1629
[4] FORTITUDE: A Phase 2 Open-Label Study in Progress to Evaluate Etavopivat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes
Sekeres, Mikkael A.
Platzbecker, Uwe
Thomsen, Rasmus Heje
Wilson, Sam
Renteria, Anne S.
Fenaux, Pierre
BLOOD, 2023, 142
[5] Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Komrokji, Rami S.
Diez-Campelo, Maria
Chee, Lynette C. Y.
Cluzeau, Thomas
Dezern, Amy E.
Fenaux, Pierre
Garcia-Manero, Guillermo
Giagounidis, Aristoteles
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Santini, Valeria
Sekeres, Mikkael A.
Zeidan, Amer M.
Buckstein, Rena
Ross, Miranda
Jiang, Ying
Bobba, Suresh
Hankin, Montagu
Materna, Chris
Graham, Christine
Thamake, Sanjay
Rovaldi, Christopher
Grayson, Dena
Salstrom, Jen L.
BLOOD, 2024, 144 : 32281 - 32283
[6] Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
Depei Wu
Xin Du
Jie Jin
Zhijian Xiao
Zhixiang Shen
Zonghong Shao
Xiao Li
Xiaojun Huang
Ting Liu
Li Yu
Jianyong Li
Baoan Chen
Guangsheng He
Zhen Cai
Hongchuang Liang
Jigang Li
Changgeng Ruan
Advances in Therapy, 2015, 32 : 1140 - 1159
[7] Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
Wu, Depei
Du, Xin
Jin, Jie
Xiao, Zhijian
Shen, Zhixiang
Shao, Zonghong
Li, Xiao
Huang, Xiaojun
Liu, Ting
Yu, Li
Li, Jianyong
Chen, Baoan
He, Guangsheng
Cai, Zhen
Liang, Hongchuang
Li, Jigang
Ruan, Changgeng
ADVANCES IN THERAPY, 2015, 32 (11) : 1140 - 1159
[8] A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
Arellano, Martha L.
Borthakur, Gautam
Berger, Mark
Luer, Jill
Raza, Azra
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06) : 534 - 539
[9] Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes
Valcarcel, David
Verma, Amit
Platzbecker, Uwe
Santini, Valeria
Giagounidis, Aristoteles
Diez-Campelo, Maria
Janssen, Jan
Schlenk, Richard F.
Gaidano, Gianluca
Perez de Oteyza, Jaime
Cleverly, Ann L.
Chiang, Alan Y.
Lahn, Michael
Desiaih, Durisala
Guba, Susan C.
List, Alan F.
Komrokji, Rami S.
BLOOD, 2015, 126 (23)
[10] Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low-or Intermediate-Risk Myelodysplastic Syndromes
Verma, Amit
Brunner, Andrew M.
Pennock, Gregory
McMullen, Dragana
Wade, Mark
Yang, Huyuan
Xie, Yuran
Whatcott, Cliff
Foulks, Jason
Melear, Jason
BLOOD, 2021, 138

← 1 2 3 4 5 →